Developing biostatistical methods to advance research related to health services and health policy is important to Carolyn Rutter. She provides consistent leadership and innovation that has helped Group Health Research Institute (GHRI) grow a world-class program in biostatistics.
Dr. Rutter’s current research focuses primarily on colorectal cancer screening. She is keenly interested in applying and developing microsimulation models for colorectal cancer—and in developing methods to calibrate these models. Dr. Rutter is the principal investigator for a colorectal cancer screening project funded through the National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET), a nationwide collaboration that uses comparative modeling to help understand cancer screening, prevention, and treatment.
Dr. Rutter is also a principal investigator for one of three PROSPR Research Centers focused on colorectal cancer. PROSPR is a nationwide consortium focused on better understanding how to improve the screening process (recruitment, screening, diagnosis, referral for treatment) for breast, colon, and cervical cancer. The GHRI-led project, “Studying Colorectal Cancer: Effectiveness of Screening Strategies” (SuCCESS), focuses on developing evidence to inform personalized screening recommendations, with an emphasis on identifying optimal screening regimens that maintain most or all of the benefits of intensive regimens while minimizing risks and costs and respecting patient preferences.
Dr. Rutter also has extensive experience in Bayesian modeling, including developing Bayesian meta-analytic models to examine the accuracy of diagnostic tests. Her other areas of expertise include provider profiling and statistical methods for mental health research.
Dr. Rutter is past chair of the Health Policy Statistics Section of the American Statistical Association and is a fellow of the American Statistical Association. She was GHRI’s lead statistician from 2003 to 2008 and still actively supports the Institute’s biostatistics program. She is also an affiliate professor at the University of Washington in the Departments of Biostatistics and Health Services.
Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.
Ann Intern Med. 2014;161(2):104-12. doi: 10.7326/M13-2867. PubMed
Liss DT, Reid RJ, Grembowski D, Rutter CM, Ross TR, Fishman PA.Changes in office visit use associated with electronic messaging and telephone encounters among patients with diabetes in the PCMH.
Ann Fam Med. 2014;12(4):338-43. doi: 10.1370/afm.1642. PubMed
Tiro JA, Kamineni A, Levin TR, Schottinger JE, Zhen Y, Chubak J, Corley D, Doubeni C, Gupta S, Halm E, Skinner CS, Rutter C, Wernli KJ, Klabunde CN.A conceptual model for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Consortium.
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1147-58. doi: 10.1158/1055-9965.EPI-13-1217. Epub 2014 Jun 10.
Wernli KJ, Hubbard RA, Johnson E, Chubak J, Kamineni A, Green BB, Rutter CM.Patterns of colorectal cancer screening uptake in newly-eligible men and women.
Cancer Epidemiol Biomarkers Prev. 2014 May 3 [Epub ahead of print]. PubMed